Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Christian Edouard-Betsy was at work when his doctor called and asked him to meet immediately to discuss the results of a ...

“Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in ...

Opens in a new tab or window SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...